Ovid Therapeutics INC Form 4 insider transactions

Ovid Therapeutics Inc. reports that Chief Financial Officer Charles Ross Carter was awarded 50,000 restricted stock units on July 6, 2026.

Ovid Therapeutics Inc. reports a Form 4 filing detailing the grant of stock options to Director Anna Greka.

Ovid Therapeutics Inc. reports that Director Stelios Papadopoulos was awarded restricted stock units (RSUs) valued at $45,000 as part of the company's Non-Employee Director Compensation Policy.

Ovid Therapeutics Inc. director Bart Friedman reported the acquisition of 8,789 restricted stock units (RSUs) as part of his compensation.

Ovid Therapeutics Inc. reports that Director Kevin Joseph Fitzgerald was granted restricted stock units (RSUs) as part of his compensation.

Ovid Therapeutics Executive Chairman Jeremy Levin exercised Series A Warrants to acquire 47,333 shares of common stock at $1.40 per share.

Ovid Therapeutics Inc. Director Stelios Papadopoulos was granted 65,000 employee stock options with an exercise price of $1.65, vesting in February 2027.

Ovid Therapeutics Director Jeremy M. Levin was granted 957,000 employee stock options with an exercise price of $1.65.

Ovid Therapeutics Inc. Director Kevin Joseph Fitzgerald was granted 65,000 employee stock options with an exercise price of $1.65, vesting fully on February 26, 2027.

Ovid Therapeutics Inc. Director Bart Friedman was granted 65,000 employee stock options with an exercise price of $1.65, vesting fully on February 26, 2027.

Ovid Therapeutics Inc. Director Barbara Gayle Duncan was granted 65,000 employee stock options with an exercise price of $1.65.

Ovid Therapeutics Inc. Director Karen Bernstein was granted 65,000 employee stock options with an exercise price of $1.65, vesting in February 2027.

Ovid Therapeutics' Chief Business and Financial Officer, Jeffrey Rona, reported a tax-related stock sale and the grant of new restricted stock units and stock options.

Ovid Therapeutics' President and CEO, Margaret A. Alexander, was granted 890,000 employee stock options with an exercise price of $1.76.

Ovid Therapeutics CEO Jeremy M. Levin converted 71 shares of Series B Convertible Preferred Stock into 71,000 shares of common stock, increasing his direct common stock holdings.

Takeda Pharmaceutical Co Ltd converted 1,250 shares of Ovid Therapeutics Inc. Series A Preferred Stock into 1.25 million common shares and reported a net beneficial ownership of 7 million common shares after a disposition.

Ovid Therapeutics Inc. Director Kevin Joseph Fitzgerald was granted 45,000 stock options with an exercise price of $0.57, vesting in full on February 20, 2026.

Ovid Therapeutics Inc. Director Bart Friedman reported the acquisition of 45,000 stock options with an exercise price of $0.57, vesting fully on February 20, 2026.

Ovid Therapeutics Inc. director Barbara Gayle Duncan was granted 45,000 stock options with an exercise price of $0.57, vesting fully on February 20, 2026.

Ovid Therapeutics Inc. Director Karen Bernstein has acquired 45,000 stock options with an exercise price of $0.57, set to vest in full by February 20, 2026.

Director Stelios Papadopoulos of Ovid Therapeutics Inc. reports the acquisition of 90,000 stock options exercisable at $0.49, vesting monthly over three years.

Margaret A. Alexander, COO of Ovid Therapeutics Inc., sold 5,279 shares of common stock on February 26, 2025, at a price of $0.56 per share to cover statutory tax withholding obligations related to the vesting of restricted stock units.

Ovid Therapeutics' CBFO, Jeffrey Rona, sold 3,902 shares of common stock on February 26, 2025, at a price of $0.56 per share to cover statutory tax withholding obligations related to vesting restricted stock units.

Ovid Therapeutics CEO Jeremy Levin reports the acquisition of 1,650,000 employee stock options.

Ovid Therapeutics' CBFO, Jeffrey A. Rona, reports acquisition of common stock and employee stock options.

Margaret Alexander, COO of Ovid Therapeutics, reports the acquisition of stock options and restricted stock units.

Margaret A. Alexander, President and COO of Ovid Therapeutics, acquired 6,810 shares of common stock at a price of $0.73 per share on January 27, 2025.

Ovid Therapeutics director Kevin Fitzgerald was granted 90,000 stock options on December 12, 2024, which vest over 36 months.

Ovid Therapeutics director Bart Friedman was granted 90,000 stock options, vesting monthly over three years.

Ovid Therapeutics director Barbara Duncan was granted 90,000 stock options, vesting monthly over three years.